OTCPK:ECTE

Stock Analysis Report

Executive Summary

Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Echo Therapeutics has significant price volatility in the past 3 months.
  • Echo Therapeutics's last earnings update was 1034 days ago.
  • Echo Therapeutics is not covered by any analysts.

Share Price & News

How has Echo Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-55.7%

OTCPK:ECTE

0.8%

US Medical Equipment

1.1%

US Market


1 Year Return

-54.7%

OTCPK:ECTE

9.6%

US Medical Equipment

2.1%

US Market

ECTE underperformed the Medical Equipment industry which returned 9.1% over the past year.

ECTE underperformed the Market in United States of America which returned 2% over the past year.


Share holder returns

ECTEIndustryMarket
7 Day-55.7%0.8%1.1%
30 Day106.7%0.2%3.7%
90 Day55.0%2.7%2.3%
1 Year-54.7%-54.7%10.5%9.6%4.4%2.1%
3 Year-99.6%-99.6%69.5%64.3%47.0%37.4%
5 Year-99.7%-99.7%132.5%105.9%61.6%43.8%

Price Volatility Vs. Market

How volatile is Echo Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Echo Therapeutics undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Echo Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Echo Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Echo Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Echo Therapeutics regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Echo Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Echo Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Echo Therapeutics performed over the past 5 years?

0.2%

Historical Healthcare annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Insufficient past earnings data to establish if Echo Therapeutics's year on year earnings growth rate was positive over the past 5 years.

Unable to compare Echo Therapeutics's 1-year growth to the 5-year average as past earnings data has not been reported.

Unable to compare Echo Therapeutics's 1-year growth to the US Medical Equipment industry average as past earnings data has not been reported.


Return on Equity

Unable to establish if Echo Therapeutics has efficiently used shareholders’ funds last year as no Return on Equity data is available.


Return on Assets

Unable to establish if Echo Therapeutics has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as past financial data has not been reported.


Return on Capital Employed

Unable to establish if Echo Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.


Next Steps

Financial Health

How is Echo Therapeutics's financial position?


In this section we usually analyse Echo Therapeutics's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Echo Therapeutics has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of ECTE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Echo Therapeutics's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Echo Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Echo Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Echo Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Echo Therapeutics has not reported any payouts.

Unable to verify if Echo Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Echo Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Echo Therapeutics's salary, the management and board of directors tenure and is there insider trading?

14.1yrs

Average board tenure


CEO

Alan Schoenbart (60yo)

2.5yrs

Tenure

US$260,000

Compensation

Mr. Alan W. Schoenbart, CPA, has been Chief Executive Officer of Echo Therapeutics, Inc. since March 21, 2017 and its Chief Financial Officer since December 29, 2014. Mr. Schoenbart serves as Secretary of  ...


CEO Compensation Analysis

Insufficient data for Alan to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.

No earnings data for Echo Therapeutics, not possible to compare to compensation.


Board Age and Tenure

14.1yrs

Average Tenure

The average tenure for the Echo Therapeutics board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Alan Schoenbart (60yo)

    Chief Executive Officer

    • Tenure: 2.5yrs
    • Compensation: US$260.00k

Board Members

  • Alan Schoenbart (60yo)

    Chief Executive Officer

    • Tenure: 2.5yrs
    • Compensation: US$260.00k
  • Richard Shemin

    Member of Clinical Advisory Board

    • Tenure: 14.1yrs
  • Stanley Nasraway

    Member of Clinical Advisory Board

    • Tenure: 14.1yrs
  • Alan Lisbon

    Member of Clinical Advisory Board

    • Tenure: 14.1yrs
  • Mitchell Levy

    Member of Clinical Advisory Board

    • Tenure: 14.1yrs
  • Bruce Bistrian

    Member of Clinical Advisory Board

    • Tenure: 14.1yrs
  • Peter Burke

    Member of Clinical Advisory Board

    • Tenure: 14.1yrs
  • Anthony Furnary

    Member of Medical Advisory Board

    • Tenure: 11.3yrs

Company Information

Echo Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Echo Therapeutics, Inc.
  • Ticker: ECTE
  • Exchange: OTCPK
  • Founded: 1989
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$41.221k
  • Shares outstanding: 13.30m
  • Website: https://www.echotx.com

Number of Employees


Location

  • Echo Therapeutics, Inc.
  • 99 Wood Avenue South
  • Suite 302
  • Iselin
  • New Jersey
  • 8830
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ECTEOTCPK (Pink Sheets LLC)YesCommon StockUSUSDNov 1997

Biography

Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. It is developing continuous gl ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 23:56
End of Day Share Price2019/09/13 00:00
Earnings2016/09/30
Annual Earnings2015/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.